...
首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Cardiac resynchronization therapy in patients with atrial fibrillation: is atrial lead implantation necessary?
【24h】

Cardiac resynchronization therapy in patients with atrial fibrillation: is atrial lead implantation necessary?

机译:心房颤动患者的心脏再同步治疗:是否需要植入心房铅?

获取原文
获取原文并翻译 | 示例
           

摘要

Many studies have shown that cardiac resynchronization therapy (CRT) reduces symptoms, improves exercise capacity, and decreases mortality in patients with heart failure and left ventricular (LV) dyssynchrony.1"5 Although atrial fibrillation (AF) occurs in approximately 30% of heart failure patients,6 the arrhythmia was an exclusion criterion in most of the major CRT trials perhaps for the reason stated in the CARE-HF trial that such patients "cannot benefit from the atrial component of CRT."5 However, mounting evidence indicates that CRT in AF patients produces a benefit similar to patients in sinus rhythm7"13 with aggressive control of the ventricular rate especially with atri-oventricular (AV) node ablation.7'14 Consequently, CRT is now increasingly applied to patients with persistent or permanent AF.
机译:许多研究表明,心脏再同步治疗(CRT)可以减轻心力衰竭和左心室(LV)不同步的患者的症状,提高运动能力并降低其死亡率。1“ 5尽管心房纤颤(AF)发生在大约30%的心脏衰竭患者[6],在大多数大型CRT试验中,心律失常是一项排除标准,也许是因为CARE-HF试验中指出,这类患者“不能从CRT的心房成分中受益”。5然而,越来越多的证据表明,CRT在房颤患者中产生的益处类似于窦性心律患者[13],可积极控制心室率,尤其是房室结消融。7'14因此,CRT现在越来越多地应用于持续性或永久性房颤患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号